GBP5 emerges as a pan-cancer biomarker, with overexpression linked to immune checkpoint behavior and immunotherapy response across multiple tumor types, such as lung and triple-negative breast cancer [59,71,72,73]. This evidence concerns the gene GBP5 and neoplasm.